• Establishment Labs Holdings Inc. was added to the US small-cap Russell 2000 Index, along with related growth and value indexes, following the June 2026 Russell index reconstitution, cementing its place within the broader Russell 3000 benchmark universe.
• This index inclusion increases the company’s visibility among institutional investors and index-linked funds, potentially influencing trading volumes as portfolios align with the updated benchmarks.
• With Establishment Labs Holdings now entering the Russell 2000, we’ll examine how this benchmark inclusion could reshape its existing investment narrative.

The latest GPUs need a type of rare earth metal called Terbium and there are only 29 companies in the world exploring or producing it. Find the list for free.

Establishment Labs Holdings Investment Narrative Recap

To own Establishment Labs, you need to believe its breast aesthetics and reconstruction portfolio and minimally invasive procedures can justify today’s premium price-to-sales multiple despite ongoing losses. Inclusion in the Russell 2000 lifts visibility and may affect liquidity, but it does not materially change the near term bull case around U.S. adoption and minimally invasive growth, nor the key risks around cash use, product concentration and the execution required to reach sustainable profitability.

The most relevant recent development alongside index inclusion is the new US$300 million senior secured term loan with Oaktree Capital Management, which refinances existing debt and extends maturities. This additional liquidity supports continued investment in U.S. commercialization, minimally invasive platforms like Preservé and global expansion, but it also locks in a larger secured capital structure that could amplify the impact if working capital needs, consignment inventory or operating expenses remain elevated for longer than investors expect.

Yet beneath the index headline, there is still material risk around rising debt, cash needs and what happens if growth slows just as...

Establishment Labs Holdings' narrative projects $435.2 million revenue and $18.6 million earnings by 2029. This requires 23.8% yearly revenue growth and a $62.3 million earnings increase from -$43.7 million today.

Uncover how Establishment Labs Holdings' forecasts yield a $90.67 fair value, a 3% upside to its current price.

Exploring Other Perspectives

Some of the lowest estimate analysts paint a tougher picture, even while assuming revenue reaches about US$430.7 million and earnings US$33.5 million by 2029, so it is worth comparing that cautious view with concerns about rising regulatory scrutiny and changing attitudes toward elective procedures to see how this new index inclusion might eventually tilt expectations.

Explore 3 other fair value estimates on Establishment Labs Holdings - why the stock might be worth 40% less than the current price!

Decide For Yourself

Don't just follow the ticker - dig into the data and build a conviction that's truly your own.

• A great starting point for your Establishment Labs Holdings research is our analysis highlighting 1 key reward that could impact your investment decision.
• Our free Establishment Labs Holdings research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Establishment Labs Holdings' overall financial health at a glance.

Interested In Other Possibilities?

Don't miss your shot at the next 10-bagger. Our latest stock picks just dropped:

• Outshine the giants: these 15 early-stage AI stocks could fund your retirement.
• AI is about to change healthcare. These 39 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10b in market cap - there's still time to get in early.
• Find 44 companies with promising cash flow potential yet trading below their fair value.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.